Drug Profile
Nanoresveratrol - JYANT Technologies
Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator JYANT Technologies
- Class Antidementias; Antineoplastics; Antithrombotics; Cardiovascular therapies; Neuroprotectants; Nonsteroidal anti-inflammatories; Phenols; Small molecules; Stilbenes; Vasodilators
- Mechanism of Action Angiogenesis inhibitors; Ribonucleotide reductase inhibitors; SIRT1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 15 Sep 2023 Nanoresveratrol is still in preclinical trials for Solid tumours in USA (JYANT Technologies pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 12 Aug 2016 Preclinical trials in Solid tumours in USA (unspecified route)